Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 6/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 6/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.47 |
| ▸ | DHCR7 | Q9UBM7 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330094 | 0.84 | SIGMAR1 (0.67) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL16910242 | 0.83 | SIGMAR1 (0.69) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL10879788 | 0.82 | KMT2A (0.53) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL8707174 | 0.82 | EBP (0.56) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL10356744 | 0.81 | CYP2D6 (0.58) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL6769894 | 0.80 | CYP2D6 (0.48) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL7753432 | 0.78 | SIGMAR1 (0.79) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL6009065 | 0.78 | CYP2D6 (0.51) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL11709291 | 0.78 | NPC1 (0.43) | SIGMAR1CYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3294808 | 0.77 | CYP2D6 (0.54) | EBPSIGMAR1CYP2D6HTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511070-B2 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1980246-A1 | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues | Poniard Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-0833624-B1 | PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH TAMOXIFEN ANALOGUES | PONIARD PHARMACEUTICALS INC (US) | 2007-11-07 | — | — | EP | disclosed |
| US-7094550-B2 | Method to determine TGF-beta | NEORX CORPORATION (US) | 2006-08-22 | — | — | US | disclosed |
| US-7084171-B2 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | NEORX CORPORATION (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060084696-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20060029986-A1 | Prevention and treatment of cardiovascular pathologies | PONIARD PHARMACEUTICALS, INC. | 2006-02-09 | — | — | US | disclosed |
| US-20050020667-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20020182659-A1 | Method to determine TGF-beta | NEORX CORPORATION | 2002-12-05 | — | — | US | disclosed |
| US-20020068731-A1 | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues | NEORX CORPORATION | 2002-06-06 | — | — | US | disclosed |
| US-6395494-B1 | SCREENING BLOOD SAMPLE FOR LIGAND BOUND TRANSFORMING GROWTH FACTOR; OBTAIN MAMMALIAN BLOOD, INCUBATE WITH BINDING PARTICLE, INCUBATE WITH DETECTION PARTICLE, DETECT BOUND COMPLEX, DETERMINE SENSITIVTY TOATHEROSCLEROSIS | NEORX CORPORATION | 2002-05-28 | — | — | US | disclosed |
| US-6262079-B1 | TREATING NON-AORTAL PROCEDURAL VASCULAR TRAUMA COMPRISING ADMINISTERING TO A MAMMAL AN EFFECTIVE CYTOSTATIC ANTIPROLIFERATIVE AMOUNT OF A STRUCTURAL ANALOG OF TAMOXIFEN, OR A PHARMACEUTICALLY ACCEPTABLE SALT | NEORX CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6251920-B1 | ADMINISTERING TAMOXIFEN OR ITS STRUCTURAL ANALOGS FOR PROPHYLAXIS AND THERAPY OF ATHEROSCLEROSIS, THROMBOSIS, MYOCARDIAL INFARCTION AND STROKE | NEORX CORPORATION | 2001-06-26 | — | — | US | disclosed |
| US-6197789-B1 | ANTIDIABETIC AGENTS | NEORX CORPORATION | 2001-03-06 | — | — | US | disclosed |
| US-6117911-A | ADMINISTRATION OF AT LEAST ONE THERAPEUTIC AGENT THAT ELEVATES THE LEVEL OF TGF-BETA IN SAID MAMMAL. | NEORX CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| US-5770609-A | ADMINISTERING TAMOXIFEN DERIVATIVES TO INHIBIT SMOOTH MUSCLE CELL PROLIFERATION ASSOCIATED WITH VASCULAR TRAUMA FROM SURGERY OR TRANSPLANTATION OF ORGANS OR MEDICAL DEVICES | NEORX CORPORATION (US) | 1998-06-23 | — | — | US | disclosed |
| US-5595722-A | TRANSFORMING GROWTH FACTOR-BETA ACTIVATORS | NEORX CORPORATION (US) | 1997-01-21 | — | — | US | disclosed |
| US-5030417-A | Method and kit to assay for steroid receptor functionality in cancerous cells | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1991-07-09 | — | — | US | disclosed |
| WO-1988008537-A1 | KIT FOR ASSAYING STEROID RECEPTOR FUNCTIONALITY IN CANCEROUS CELLS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1988-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084696-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | EBP 64/4885SIGMAR1 3998/4885CYP2D6 4879/4885 |
| US-20050020667-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | EBP 64/4885SIGMAR1 3998/4885CYP2D6 4879/4885 |
| US-20020068731-A1 | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues | TGFB1, TGFB2, TGFBR1 | EBP 43/4885SIGMAR1 1894/4885CYP2D6 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.